Details for Patent: 8,283,380
Which drugs does patent 8,283,380 protect, and when does it expire?
Patent 8,283,380 protects XADAGO and is included in one NDA.
This patent has forty-four patent family members in twenty-six countries.
Summary for Patent: 8,283,380
| Title: | Methods for treatment of parkinson's disease | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | New uses of safinamide, safinamide derivatives and MAO-B inhibitors in novel types of treatment for Parkinson's Disease are described. More specifically, the invention relates to methods for treating Parkinson's Disease through the administration of safinamide, a safinamide derivative, or a MAO-B inhibitor, in combination with other Parkinson's Disease agents or treatments, such as levodopa/PDI or dopamine agonists. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Ruggero Fariello, Carlo Cattaneo, Patricia Salvati, Luca Benatti | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Newron Pharmaceuticals SpA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US10/559,982 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,283,380 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Use; | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | United States Drug Patent 8,283,380: Safinamide Parkinson’s Disease Claims, Scope, Expiration and Patent LandscapeU.S. Patent No. 8,283,380 protects a treatment method using oral safinamide, including safinamide methanesulfonate, together with a stable levodopa regimen for idiopathic Parkinson’s disease. The core protection is a combination-use claim, not a broad claim to safinamide, levodopa, or Parkinson’s treatment generally. The principal commercial relevance is Xadago, the safinamide product approved by the FDA in 2017 as an adjunct to levodopa/carbidopa in patients with Parkinson’s disease experiencing “off” episodes.[1] The patent’s strongest enforcement position is against an ANDA applicant that proposes safinamide for the FDA-approved adjunctive use, at an oral once-daily dose within the claimed range, during continued levodopa therapy. The patent does not directly cover safinamide monotherapy, non-oral administration, or treatment of Parkinsonian conditions other than idiopathic Parkinson’s disease. What patent protects safinamide treatment with levodopa?U.S. Patent 8,283,380 is directed to methods of treating idiopathic Parkinson’s disease by administering safinamide concurrently with levodopa. The patent was granted on October 9, 2012, and is associated with Newron Pharmaceuticals S.p.A., the developer of safinamide.[2]
The patent is a method-of-treatment patent. It does not claim safinamide as a chemical compound, safinamide methanesulfonate as a composition, or every use of safinamide in neurology. What are the independent claims of U.S. Patent 8,283,380?Claims 1 and 2 are the independent claims. Claim 1 is an improvement claim. It assumes that the patient is already receiving a stable levodopa dose and requires concurrent administration of safinamide at approximately 0.5 to 5 mg/kg/day. Claim 2 is structured as a complete treatment method. It requires:
The distinction matters in litigation. Claim 1 presents safinamide as an improvement to an existing levodopa regimen. Claim 2 expressly recites both levodopa and safinamide as components of the treatment method. Claim-by-claim scope analysis
The claims are cumulative. For example, an accused regimen that uses safinamide methanesulfonate once daily for 12 weeks with levodopa/carbidopa may implicate claims 1, 2, and 5 through 8, depending on dose and the facts established in the case. What conditions must be met to infringe the patent?A potentially infringing regimen generally must satisfy each required element of an asserted claim. For the broadest claims, the relevant elements are:
The word “concurrently” does not necessarily require simultaneous ingestion. In ordinary pharmaceutical-use analysis, the issue is whether safinamide and levodopa are used as part of the same treatment regimen. The precise interpretation would depend on the patent specification, prosecution history, claim construction, and evidence concerning the accused product’s labeling or induced use. “Stable dose” is another potentially material limitation. A short-term or titrating levodopa regimen may create a claim-construction dispute. A generic label that instructs patients to continue existing levodopa therapy may create stronger induced-infringement exposure than a label that expressly excludes stable levodopa use. What does each dependent claim add?How does the 200 mg/day limitation affect patent scope?Claim 4 adds a ceiling of approximately 200 mg/day. This limitation is commercially significant because it corresponds to a practical maximum for safinamide dosing and can capture a fixed-dose product even where a patient’s body weight makes the weight-based limitation less precise. The relationship between the weight-based and fixed-dose limitations creates separate infringement pathways. A regimen may fall within the 0.5 to 5 mg/kg/day range but exceed 200 mg/day, or it may satisfy the 200 mg/day ceiling without satisfying the weight-based range in a particular patient. Claims 1 and 2 remain the principal claims because claim 4 depends on them. Does claim 7 cover Xadago?Yes. Claim 7 expressly covers safinamide methanesulfonate. Xadago contains safinamide as the methanesulfonate salt.[1] This substantially reduces the ability of a generic applicant to avoid the claim merely by using the commercial salt form. A different pharmaceutically acceptable salt could still fall within claims 1 and 2 if it satisfies the other limitations. Claim 7 is narrower because it is limited to the methanesulfonate salt. Do claims 8 through 10 cover common Parkinson’s regimens?Yes. Claim 8 covers levodopa administered with carbidopa or benserazide. Claim 9 adds a COMT inhibitor, and claim 10 identifies tolcapone and entacapone. These claims are narrower than claims 1 and 2. They may be relevant where a patient uses levodopa/carbidopa plus entacapone, a common form of adjunctive Parkinson’s therapy. They are less important to a basic Xadago product claim if the broader independent claims can be established without proof of a COMT inhibitor. When does U.S. Patent 8,283,380 lose exclusivity?The patent’s expected nominal expiration is approximately March 2027 based on the patent term associated with its priority and filing history. The controlling date is the official USPTO patent-term calculation, including any patent-term adjustment, terminal disclaimer, or other term-specific event.[2,3] The patent term should be distinguished from FDA regulatory exclusivity:
FDA approval does not itself establish patent validity. Conversely, expiration of NCE exclusivity does not eliminate a listed method-of-use patent. What is the FDA and Orange Book status of Xadago?The FDA approved Xadago on March 21, 2017, as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing “off” episodes.[1] The approved product is safinamide tablets in 50 mg and 100 mg strengths. The FDA-approved use closely tracks the commercial relevance of Patent 8,283,380:
Orange Book-listed method-of-use patents can expose an ANDA applicant to patent litigation even when the underlying compound patent has expired. A generic company may attempt a section viii statement carving out the patented indication, but that approach is difficult where the approved label and the patented use substantially overlap.[4] The exact current Orange Book listing and any associated patent-use code should be confirmed from the FDA’s current electronic Orange Book. Patent listing status can change through delisting, expiration updates, corrections, or changes in the approved labeling. Which companies are challenging the safinamide patent?The claim set alone does not establish a current Paragraph IV challenger, active district-court litigation, or settlement agreement. Those facts require review of the current FDA ANDA records, Orange Book certifications, and federal court dockets. For business purposes, the relevant challenger categories are:
A Paragraph IV notice would normally trigger a patent-infringement action under the Hatch-Waxman framework. A timely suit could impose a statutory 30-month stay of FDA approval, subject to statutory exceptions and court developments.[5] What generic launch risks exist?At-risk launchA generic company could launch before patent expiration after receiving a favorable invalidity or noninfringement ruling, or it could launch “at risk” while litigation remains unresolved. The commercial risk would include damages, an injunction, and exposure for induced infringement if the proposed label directs use with levodopa. Label carve-outA section viii carve-out may be viable only if the generic labeling omits the patented method. This strategy becomes weaker where the only commercially meaningful use is adjunctive treatment with levodopa and the FDA-approved label necessarily communicates concurrent use. Noninfringing dosingA label that uses a dose outside the claimed range may reduce literal infringement risk. That strategy can be undermined if the approved label permits titration into the patented range or if the patentee asserts infringement under the doctrine of equivalents. Invalidity defensesPotential validity issues include:
The practical strength of these defenses depends on the prosecution record, prior-art dates, clinical data, and claim construction. The claim language alone is insufficient to predict litigation outcome. How strong is the patent estate for safinamide?Patent 8,283,380 has meaningful but narrow protection. Its strength comes from alignment with the commercial treatment regimen:
Its weaknesses are equally clear:
The estate should be analyzed together with any related safinamide compound, formulation, dosing, crystalline-form, manufacturing, and method-of-use patents. Patent 8,283,380 alone does not establish broad exclusivity over all safinamide products. Does safinamide have biosimilar risk?No. Safinamide is a chemically synthesized small molecule, not a biologic. The relevant competition pathway is an ANDA for a generic equivalent, not a biosimilar application under the Public Health Service Act. The primary regulatory issues are bioequivalence, pharmaceutical equivalence, labeling, patent certification, and any relevant formulation differences. Manufacturing patents could still delay or complicate supply, but they would not convert safinamide into a biologic product. What manufacturing and geographic barriers exist?Patent 8,283,380 is primarily a U.S. method-of-use barrier. It does not, based on the supplied claims, claim:
Geographic protection must be assessed separately by jurisdiction. A U.S. method patent does not prevent manufacture, sale, or use outside the United States unless separate foreign patents apply. Foreign family members may have different claim scope, expiration dates, opposition histories, and enforceability. Manufacturing freedom to operate therefore requires a separate review of compound, salt, process, polymorph, formulation, and use patents in each target country. What revenue exposure does the patent create?The patent creates direct exposure for any U.S. generic launch that relies on the approved adjunctive Parkinson’s indication before the relevant patent term ends. The amount of revenue at risk depends on Xadago prescription volume, net price, payer coverage, generic substitution, and the number and timing of ANDA entrants. A reliable revenue estimate cannot be derived from the patent claims. The patent establishes a legal barrier, not the size of the protected market. Commercial analysis should separate:
Key Takeaways
FAQsCan a generic safinamide product launch before March 2027?Yes, but only if the applicant obtains approval without an enforceable patent barrier, wins or settles litigation, uses a valid indication carve-out, or launches at risk. Patent expiration alone does not determine the timing of FDA approval. Does using safinamide without levodopa avoid Patent 8,283,380?Generally, yes for the supplied claims. Claims 1 and 2 require concurrent levodopa treatment. Safinamide monotherapy would not satisfy that express limitation, although other patents or regulatory restrictions could remain relevant. Does a 50 mg once-daily safinamide regimen fall within the claims?It may. The answer depends on the patient’s weight and the applicable “about” range. A 50 mg daily dose generally falls within the claimed dosage concept for many patients, but infringement requires satisfaction of every limitation in the asserted claim. Are claims 8 through 10 necessary to prove infringement of the main Xadago use?No. Claims 8 through 10 add narrower limitations. Claims 1 and 2 do not require carbidopa, benserazide, or a COMT inhibitor, although those agents may support infringement of the dependent claims. Does patent expiration eliminate all U.S. exclusivity for safinamide?No. Expiration of Patent 8,283,380 would remove that patent barrier, but other unexpired patents, regulatory exclusivity, FDA approval requirements, manufacturing patents, or litigation outcomes could affect market entry. References
More… ↓ |
Drugs Protected by US Patent 8,283,380
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mdd Us | XADAGO | safinamide mesylate | TABLET;ORAL | 207145-001 | Mar 21, 2017 | AB | RX | Yes | No | 8,283,380 | ⤷ Start Trial | ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON'S DISEASE EXPERIENCING 'OFF' EPISODES | ⤷ Start Trial | |||
| Mdd Us | XADAGO | safinamide mesylate | TABLET;ORAL | 207145-002 | Mar 21, 2017 | AB | RX | Yes | Yes | 8,283,380 | ⤷ Start Trial | ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON'S DISEASE EXPERIENCING 'OFF' EPISODES | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,283,380
| PCT Information | |||
| PCT Filed | April 08, 2004 | PCT Application Number: | PCT/IB2004/001408 |
| PCT Publication Date: | October 21, 2004 | PCT Publication Number: | WO2004/089353 |
International Family Members for US Patent 8,283,380
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1613296 | ⤷ Start Trial | CA 2015 00042 | Denmark | ⤷ Start Trial |
| European Patent Office | 1613296 | ⤷ Start Trial | 92782 | Luxembourg | ⤷ Start Trial |
| European Patent Office | 1613296 | ⤷ Start Trial | 300752 | Netherlands | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
